SCHEMBL2947801

SCHEMBL2947801

Cc1ccc(C(N)=O)cc1-c1ccc2c(-c3ccc(S(C)(=O)=O)cc3)nncc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 13/20 0.55
KIT P10721 8/20 0.55
KDR P35968 8/20 0.55
LCK P06239 5/20 0.55
MAPK9 P45984 7/20 0.51
MAPK10 P53779 2/20 0.51
MAP4K4 O95819 1/20 0.44
ABL1 P00519 2/20 0.43
LYN P07948 1/20 0.40
LRRK2 Q5S007 1/20 0.40
CSF1R P07333 1/20 0.39
AURKA O14965 1/20 0.39
ROCK2 O75116 1/20 0.39
CHEK2 O96017 1/20 0.39
CDK1 P06493 1/20 0.39
PIM1 P11309 1/20 0.39
FGFR3 P22607 1/20 0.39
CDK2 P24941 1/20 0.39
FLT4 P35916 1/20 0.39
CSNK1D P48730 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2945930 0.91 MAPK14 (0.53) MAPK14KITKDRLCKMAPK9
SCHEMBL2952255 0.85 MAPK14 (0.53) MAPK14KITKDRLCKMAPK9
SCHEMBL2949197 0.84 MAPK14 (0.56) MAPK14KITKDRLCKMAPK9
SCHEMBL2948437 0.83 MAPK14 (0.70) MAPK14KITKDRLCKMAPK9
SCHEMBL2949665 0.81 MAPK14 (0.57) MAPK14KITKDRLCKMAPK9
SCHEMBL2948078 0.80 MAPK14 (0.60) MAPK14KITKDRLCKMAPK9
SCHEMBL2952994 0.80 MAPK14 (0.58) MAPK14KITKDRLCKMAPK9
SCHEMBL2952583 0.80 MAPK14 (0.55) MAPK14KITKDRLCKMAPK9
SCHEMBL2952034 0.79 MAPK14 (0.49) MAPK14KITKDRLCKMAPK9
SCHEMBL2955380 0.79 MAPK14 (0.52) MAPK14KITKDRLCKMAPK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1856058-B1 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2014-09-03 EP claimed
US-7759337-B2 Phthalazine compounds and methods of use AMGEN INC. (US) 2010-07-20 US claimed
EP-1856058-A2 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2007-11-21 EP claimed
WO-2006094187-A2 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2006-09-08 WO claimed
US-20060199817-A1 Phthalazine, aza- and diaza-phthalazine compounds and methods of use AMGEN INC. (US) 2006-09-07 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199817-A1 Phthalazine, aza- and diaza-phthalazine compounds and methods of use DAPK2, CDK2, DAPK1 MAPK14 293/4885KIT 1977/4885KDR 683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.